Skip to main content
. 2018 Sep 18;19(9):2811. doi: 10.3390/ijms19092811

Figure 3.

Figure 3

SA4503 treatment decreased cognitive deficits in AtrxΔE2 mice based on memory-related tests. (A) Number of total arm entries (left) and alternations (right) in a Y-maze test. ** p < 0.01, versus vehicle-treated WT mice; ## p < 0.01, versus vehicle-treated AtrxΔE2 mice by one-way ANOVA with post hoc Tukey’s test; F (3, 18) = 12.98. (B) Novel object recognition task. Discrimination index of object exploration during the sample phase (left), and while exploring familiar and new objects in the test phase after 24 h (right). ** p < 0.01, versus vehicle-treated WT mice; # p < 0.05, versus vehicle-treated AtrxΔE2 mice by one-way ANOVA with post hoc Tukey’s test; F (3, 30) = 8.898. (C) Barnes maze test measurement of total latency (s) to reach the target hole. * p < 0.05 by two-way ANOVA with post hoc Bonferroni’s test; F (3, 120) = 6.535, p < 0.01 (group); F (3, 120) = 25.16, p < 0.01 (day), F (9, 120) = 1.184, p = 0.3112 (interaction between group and day). Each bar represents the mean ± SEM. Abbreviations: Veh., vehicle; SA, SA4503. WT + Vehicle: n = 9 mice, WT + SA4503: n = 9 mice, AtrxΔE2 + Vehicle: n = 8 mice, AtrxΔE2 + SA4503: n = 8 mice.